Quick Answer
Neuphoria Therapeutics Inc. reported Operating Income Loss of -$1.13 million for the year ending 2025.
- Neuphoria Therapeutics Inc. showed an increase of +93.7% in Operating Income Loss from 2024 to 2025.
- This data is from Neuphoria Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), Neuphoria Therapeutics Inc.'s Operating Income Loss has grown by 94.9%.
- Historical annual values: Fiscal year 2025: -$1.13 million | Fiscal year 2024: -$17.89 million | Fiscal year 2023: -$21.98 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: